Program

Thursday October 8

07.30-08.30	Registration
08.30-08.35	Welcome and opening R.M.F. Berger
08.35-10.30	What is Pediatric Pulmonary Vascular Disease? Chairs: S. Abman & W. Zijlstra
08.35	The clinical spectrum of pulmonary vascular diseases in neonates, infants, children and adolescents <i>M. del Cerro, Madrid, Spain</i>
09.05	Recent progress in understanding the pathobiology of PAH: new treatment options to be expected? <i>R. Schermuly</i>
09.35	Genetics of pulmonary vascular disease: pediatric colours M. Kerstjens, Groningen, The Netherlands
10.00	Pediatric populations at risk: Which infants and children are at risk for PVD? <i>I. Adatia, Edmonton, Canada</i>
10.30-11.00	Break
11.00-12.30	RV performance: It's all about interaction Chairs: D. Ivy & R. Borgdorff
11.00	RV adaptation to pressure load in pulmonary vascular disease <i>B. Bartelds, Groningen, The Netherlands</i>
11.30	RV coupling with the diseased pulsatile pulmonary circulation <i>R. Naeije, Bruxelles, Belgium</i>
12.00	RV interdependence and interaction with the LV in pulmonary hypertension <i>T. Delhaas, Maastricht, The Netherlands</i>
12.30-13.30	Lunch Break, including:
13.00-14.00	Rapid Fire Session (in lunch area)
	Poster Presentations Chair: B. Bartelds
14.00-15.15	Pulmonary vascular disease in bronchopulmonary dysplasia: The story of the chicken and the egg Chairs: J. Fineman & K. Bergman

14.00	Lung development in health and disease <i>D.Tibboel, Rotterdam, The Netherlands</i>
14.25	Early pulmonary vascular disease in neonates at risk for BPD <i>S. Abman, Denver, CO, US</i>
14.50	Current trends in diagnosis and treatment of PVD associated with BPD <i>B. Hanna, Philadelphia</i>

15.15-15.45 Break

15.45-16.15 Rapid Fire Session (in lunch area) Chair: R.M.F. Berger

Hot debate: Clinical Classification for neonatal and pediatric PVD: should we follow the WSPH-classification for adults with PH?

Pro D. Ivy, Denver, CO, US Con M. del Cerro, Madrid, Spain

16.30-18.00 Workshops

Workshop 1

Exercise testing in children with pulmonary vascular disease *T. Takken, Utrecht, The Netherlands, A. Hager, Muenchen, Germany*

Workshop 2

How and when to perform an adequate and safe right heart cath in pedPH V. Cernak, *Groningen The Netherlands*, R.M.F. Berger, *Groningen The Netherlands*

Workshop 3

When to consider pulmonary vascular diseases? Need-to-know facts for

(non-)PH-experts

The various faces of PVD M. Roofthooft, Groningen, The Netherlands M. Kerstjens, Groningen, The Netherlands

Friday October 9

08.00-08.30 Registration

08.30-10.00	Diagnostic tools in pulmonary vascular disease: New wines in old bottles? Chairs: M. Beghetti & M. Roofthooft
08.30	Pulmonary vascular dynamics: of additional value in the clinical assessment of paediatric PVD? <i>M. Douwes, Groningen, The Netherlands</i>
09.00	MRI, conventional or advanced imaging? S. Moledina, London. Great Britain
09.30	The promise of biomarkers and ECFC's H.J. Bogaard, Amsterdam, The Netherlands
10.00	Smart trial designs in pediatric PAH A. El-Gazayerly, Utrecht, The Netherlands
10.30-11.00	Break
11.00-12.00	Pulmonary vascular disease in the Neonatal and Pediatric ICU: Chairs: T. Humpl & B. Hanna
11.00	How to treat a neonate with refractory PH (PPHN, CDH, lung hypoplasia)
	· Pharmalogical options
	· Balancing oxygenation vs ventilatory lung injury
	· Supportive measurements
	I. Reiss, Rotterdam, The Netherlands
11.30	I. Reiss, Rotterdam, The Netherlands How to recognize and treat a failing right ventricle?
11.30	
11.30	How to recognize and treat a failing right ventricle?
11.30	How to recognize and treat a failing right ventricle? Pharmacological treatment options
11.30 12.00-12.30	How to recognize and treat a failing right ventricle? Pharmacological treatment options Circulatory support- or replacement devices
	 How to recognize and treat a failing right ventricle? Pharmacological treatment options Circulatory support- or replacement devices E. da Cruz, Denver, CO, US

12.30-14.00	Lunch break
13.30-14.00	Rapid fire session (in lunch area) Chair: E. da Cruz
	Hot debate: Cardiac catheterisation should be part of the standard follow-up in children with PAH
	Pro <i>M. Beghetti c</i> on <i>I. Adatia</i>
14.00-15.30	Blood flow, shear stress and pulmonary vascular disease
	(Phaedra-session) Chairs: R. Schermuly & D. vd Feen
14.00-14.30	Effects of increased blood flow in the pulmonary circulation J. Fineman, San Francisco, CA, US
14.30-15.00	Flow-disturbance in PAH and the TGFb/BMP axis in the pulmonary Endothelium J.R. Moonen, Stanford, CA, US
15.00-15.30	Any progress in the understanding of very wibility of flow
15.00-15.50	Any progress in the understanding of reversibility of flow-associated PAH? D. vd Feen, Groningen, The Netherlands
Parallel session	n (room 17):
Parallel session 14.00-15.30	Clinical Nursing Practice and Psychosocial Assessment: Tools, Tips and Opportunities.
	Clinical Nursing Practice and Psychosocial Assessment: Tools,
14.00-15.30	Clinical Nursing Practice and Psychosocial Assessment: Tools, Tips and Opportunities. QI project: the comfort level of bedside nurse in the management of
14.00-15.30 14.00	Clinical Nursing Practice and Psychosocial Assessment: Tools, Tips and Opportunities. QI project: the comfort level of bedside nurse in the management of IV prostacyclines A. Brown, Nashville, US Pain management in SQ trepostinil therapy C. van Aken, Leuven,
14.00-15.30 14.00 14.20	Clinical Nursing Practice and Psychosocial Assessment: Tools, Tips and Opportunities. QI project: the comfort level of bedside nurse in the management of IV prostacyclines A. Brown, Nashville, US Pain management in SQ trepostinil therapy C. van Aken, Leuven, Belgium Screening and addressing psychosocial distress: How to do it?' V.
14.00-15.30 14.00 14.20 14.40	Clinical Nursing Practice and Psychosocial Assessment: Tools, Tips and Opportunities. QI project: the comfort level of bedside nurse in the management of IV prostacyclines A. Brown, Nashville, US Pain management in SQ trepostinil therapy C. van Aken, Leuven, Belgium Screening and addressing psychosocial distress: How to do it?' V. Kelly, London, Great Britain Nutritional status and energy intake in children with PAH T. Vissia-

16.00	Predictors, treatment goals and clinical endpoints in pediatric PAH <i>M. Ploegstra, Groningen, The Netherlands</i>
16.20	New drugs for PAH: opportunities in the pediatric age group <i>M. Beghetti, Geneva, Switzerland</i>
16.40	New treatment strategies in pediatric PAH: combination, upfront, sequential; hybrid? D. Ivy, Denver, CO, US

17.00 Closure and farewellnight: the Groningen Experience

Ever wondered why Groningen is listed 1st as city to live in the Netherlands?

Thought about why the city is a magnet for students and foreigners alike?

Probably not.

Well, now it's time to change that!

Hereby you are cordially invited to our "Who wants to be a Groninger" quiz.

This once in a lifetime quiz, gives you the opportunity to learn everything you

ever wanted to know about the Pride of the North. During the evening we'll take you on a tour through Groningen. Several restaurants will serve local specialities such as bitterballen, cheese and craft beer.

We look forward to meeting you!